Janus Henderson Group’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $98.5M | Sell |
11,132,131
-2,460,203
| -18% | -$21.8M | 0.05% | 263 |
|
|
2025
Q1 | $109M | Sell |
13,592,334
-487,885
| -3% | -$3.91M | 0.06% | 255 |
|
|
2024
Q4 | $148M | Buy |
14,080,219
+753,332
| +6% | +$7.92M | 0.08% | 228 |
|
|
2024
Q3 | $175M | Buy |
13,326,887
+29,570
| +0.2% | +$388K | 0.09% | 201 |
|
|
2024
Q2 | $187M | Buy |
13,297,317
+382,157
| +3% | +$5.38M | 0.1% | 179 |
|
|
2024
Q1 | $218M | Buy |
12,915,160
+1,789,830
| +16% | +$30.2M | 0.12% | 178 |
|
|
2023
Q4 | $157M | Buy |
11,125,330
+487,023
| +5% | +$6.88M | 0.09% | 207 |
|
|
2023
Q3 | $110M | Buy |
10,638,307
+3,115,762
| +41% | +$32.1M | 0.07% | 236 |
|
|
2023
Q2 | $124M | Buy |
7,522,545
+695,758
| +10% | +$11.5M | 0.08% | 223 |
|
|
2023
Q1 | $62.5M | Buy |
6,826,787
+5,619,257
| +465% | +$51.4M | 0.04% | 331 |
|
|
2022
Q4 | $8.63M | Buy |
+1,207,530
| New | +$8.63M | 0.01% | 753 |
|
|
2022
Q2 | – | Sell |
-1,410,387
| Closed | -$9.63M | – | 2599 |
|
|
2022
Q1 | $9.63M | Buy |
1,410,387
+407,069
| +41% | +$2.78M | ﹤0.01% | 896 |
|
|
2021
Q4 | $8.12M | Buy |
1,003,318
+192,061
| +24% | +$1.55M | ﹤0.01% | 946 |
|
|
2021
Q3 | $7.94M | Buy |
811,257
+68,485
| +9% | +$670K | ﹤0.01% | 950 |
|
|
2021
Q2 | $5M | Buy |
742,772
+489,545
| +193% | +$3.29M | ﹤0.01% | 1058 |
|
|
2021
Q1 | $2.3M | Buy |
253,227
+23,825
| +10% | +$216K | ﹤0.01% | 1158 |
|
|
2020
Q4 | $1.54M | Buy |
+229,402
| New | +$1.54M | ﹤0.01% | 1162 |
|
|
2017
Q4 | – | Sell |
-2,154,082
| Closed | -$22.6M | – | 1308 |
|
|
2017
Q3 | $22.6M | Sell |
2,154,082
-30,829
| -1% | -$324K | 0.01% | 709 |
|
|
2017
Q2 | $24.1M | Buy |
+2,184,911
| New | +$24.1M | 0.02% | 697 |
|